Clinical Trials & Results

Search or filter the listing below to find a trial or results of a completed trial.

View Actively Recruiting Clinical Trials

Click here to see trials currently recruiting participants

Filter

Health Condition

Toggle

Study Status

Toggle

Age group

Toggle

Gender

Toggle

Phase

Toggle

Study Types

Toggle

All Results

No results found

Please change the filter settings to find the product(s) you are looking for. You can also use the search function to look up a product.

Clear Filters

A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy Safety and Efficacy Study (TOPAS-MSA)

brain-icon.png
Condition(s):
Multiple System Atrophy
Status:
Recruiting
Requirements:
30 years to 75 years
Interventions:
Drug: TEV-56286 (emrusolmin, anle138b)
Learn more Primary objectives: The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). Secondary objectives: A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

brain-icon.png
Condition(s):
Multiple System Atrophy
Status:
Recruiting
Requirements:
30 years and older
Interventions:
Drug: TEV-56286
Learn more The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks

Rasagiline Mesylate in Patients With Multiple System Atrophy of the Parkinsonian Subtype

brain-icon.png
Condition(s):
Multiple System Atrophy
Status:
Completed
Requirements:
30 Years and older
Interventions:
Drug: rasagiline mesylate | Drug: placebo
Learn more Please refer to ClinicalTrials.gov for a description of the trial